ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1577

Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout

Adela Navratilova1, Veronika Voclonová2, Hana Hulejová2, Lucie Andrés Cerezo1, Markéta Pavlíková3, Viktor Bečvář2, Jakub Zavada1, Karel Pavelka4, Ladislav Senolt4 and Blanka Stiburkova5, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic

Meeting: ACR Convergence 2021

Keywords: cytokines, genetics, gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: IL-37 is an anti-inflammatory cytokine, member of IL-1 family, related to inflammatory and autoimmune diseases. Here we aimed to investigate the association of genetic variants of IL-37 and IL-37 plasma levels in relation to hyperuricemia/gout.

Methods: The study involved normouricemic controls (n=50), primary hyperuricemia (n=100), primary gout (n=100), tophaceous gout (n=25) and acute gout flare (n=18). All patients met the ACR gout classification criteria (1). Levels of plasma IL-37 were analysed using Enzyme-Linked Immunosorbent Assay. All coding regions and intron-exon boundaries of IL-37, exon 1-5, were amplified and sequenced directly. Differences of measured levels of IL-37 between groups were compared using Wilcoxon test. Variant allele frequencies were compared using binomial test and Fisher exact test.

Results: IL-37 levels were fairly similar across groups except for patients with tophaceous gout that had IL-37 levels significantly increased in contrast to control subjects (p=0.019) and gout patients (p=0.036). We identified 12 IL-37 genetic variants: five intron (rs28947188, rs2466448, rs3811045, rs3811048, rs2708944), and seven non-synonymous allelic variants (rs3811046, rs3811047, rs2708943, rs2723183, rs2723187, rs2708947, rs27231927). Of those, rs28947188 showed a significant under-presentation in hyperuricemic and gout cohorts (no variant found among all 243 patients) compared to normouricemic control group (minor allele frequency: MAF = 0.05) and European population (MAF = 0.083).

Conclusion: Variant rs28947188 showed a significant under-presentation in hyperuricemic/gout cohorts compared to European population MAF/normouricemic cohort. Plasma IL-37 is significantly up-regulated in patients with tophaceous gout compared to other groups. This evidence highlights the role of IL-37 in the pathogenesis of gout.

References:

Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789-98.

Acknowledgement:

Supported by MHCR 023728, SVV 260 523 and BBMRI-CZ LM2018125


Disclosures: A. Navratilova, None; V. Voclonová, None; H. Hulejová, None; L. Andrés Cerezo, None; M. Pavlíková, None; V. Bečvář, None; J. Zavada, None; K. Pavelka, Abbvie, 6, UCB, 6, MSD, 6, Roche, 6, Pfizer, 6, Eli Lilly, 6, Egis, 6, Biogen, 6, Pfizer, 6; L. Senolt, None; B. Stiburkova, None.

To cite this abstract in AMA style:

Navratilova A, Voclonová V, Hulejová H, Andrés Cerezo L, Pavlíková M, Bečvář V, Zavada J, Pavelka K, Senolt L, Stiburkova B. Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/interleukin-37-associations-of-plasma-levels-and-genetic-variants-in-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-37-associations-of-plasma-levels-and-genetic-variants-in-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology